Cancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging ToolsChao Ma, Rong Fan, Antoni Ribas In the past decade, significant progresses have taken place in the field of cancer immunotherapy. Tumor-targeting immunotherapies are being developed for most human cancers, including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. The FDA has approved multiple molecular immunotherapeutics, such as Ipilimumab; cellular immunotherapies (e.g. adoptive cell transfer) are being tested in phase II/III clinical trials. Immunotherapetics has evolved into a sophisticated field: Multimodal therapeutic regimens are administrated to induce focused responses, curtail side- effects and improve therapeutic efficacy. |
Contents
Cancer immunotherapy and nextgeneration clinical immune assessment | 5 |
technology methods and applications | 7 |
a new potential paradigm for immune status characterization | 14 |
An evolutionary perspective on antitumor immunity | 20 |
Singlecell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cellcell interaction | 33 |
Singlecell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cellcell interaction | 41 |
overcoming the Achilles heel of immunotherapy with antigen nonspecific therapies | 42 |
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer | 52 |
Improvement of cancer immunotherapy by combining molecular targeted therapy | 61 |
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy | 68 |
Nanocurcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response | 87 |